As fresh new biopharma start-ups work up their product innovation and bring their developments to market, it seems logical that they should identify optimal processes and systems from the outset, learning from the inefficiencies that have hampered data management in Big Pharma. Frits Stulp and Duncan van Rijsbergen at Iperion, advise on what modern best practices might look like.